HDAC4 Cancer Research Results
HDAC4, Histone deacetylases: Click to Expand ⟱
| Source: |
| Type: |
HDAC4 overexpression is associated with higher tumor grade, advanced clinical stage and poor survival. HDAC4 promotes proliferation and G1/S cell cycle progression in EC cells by inhibiting cyclin-dependent kinase (CDK) inhibitors p21 and p27 and up-regulating CDK2/4 and CDK-dependent Rb phosphorylation.
HDAC4 is often overrepresented and associated with poor prognosis.
HDAC Inhibitors: Given the role of HDAC4 in cancer, HDAC inhibitors (HDACi) are being explored as potential therapeutic agents.
|
Scientific Papers found: Click to Expand⟱
| - |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
CRC, |
HT29 |
|
|
|
- |
in-vitro, |
CRC, |
HCT15 |
|
|
|
- |
in-vitro, |
CRC, |
COLO205 |
|
|
|
- |
in-vitro, |
CRC, |
SW-620 |
|
|
|
- |
in-vivo, |
NA, |
NA |
|
|
|
TumCMig↓, Curcumin significantly inhibits cell migration, invasion, and colony formation in vitro and reduces tumor growth and liver metastasis in vivo.
TumCI↓,
TumCG↓,
TumMeta↓,
Sp1/3/4↓, curcumin suppresses Sp-1 transcriptional activity and Sp-1 regulated genes including ADEM10, calmodulin, EPHB2, HDAC4, and SEPP1 in CRC cells.
HDAC4↓,
FAK↓, Curcumin inhibits focal adhesion kinase (FAK) phosphorylation
CD24↓, Curcumin reduces CD24 expression in a dose-dependent manner in CRC cells
E-cadherin↑, E-cadherin expression is upregulated by curcumin and serves as an inhibitor of EMT.
EMT↓,
TumCP↓,
NF-kB↓, CUR prevents cancer cells migration, invasion, and metastasis through inhibition of PKC, FAK, NF-κB, p65, RhoA, MMP-2, and MMP-7 gene expressions
AP-1↝,
STAT3↓, downregulation of CD24 reduces STAT and FAK activity, decreases cell proliferation, metastasis in human tumor
P53?,
β-catenin/ZEB1↓, CUR could activate protein kinase D1 (PKD1) suggesting that suppressing of β-catenin transcriptional activity prevents growth of prostate cancer
NOTCH1↝,
Hif1a↝,
PPARα↝,
Rho↓, CUR prevents cancer cells migration, invasion, and metastasis through inhibition of PKC, FAK, NF-κB, p65, RhoA, MMP-2, and MMP-7 gene expressions
MMP2↓,
MMP9↓,
DNMTs↓, EGCG may competitively inhibit some epigenetic enzymes (DNMT1, DNMT3A, HDAC2, HDAC3, HDAC4, HDAC7 and EZH2).
DNMT1↓,
DNMT3A↓,
HDAC2↓,
HDAC3↓,
HDAC4↓,
EZH2↓, Interaction of EGCG with EZH2 protein indicates inhibition of activity
PI3K↓, Downregulation of key signaling moieties of PI3K, Wnt and MAPK pathways
Wnt↓,
MAPK↓,
hTERT/TERT↓, including TERT, CCNB1, CCNB2, MMP2, MMP7. PIK3C2B, PIK3CA, MAPK8 and IL6 was also observed
MMP2↓,
MMP7↓,
IL6↓,
MDM2↓, Fig 1
MMP-10↓,
TP53↑,
PTEN↑,
aSmase↝, Figure 3b shows that quercetin treatment caused a dose-dependent augmentation in mRNA levels of Diablo and FAS
Diablo↑,
Fas↓,
Hsc70↓, coupled with a dose-responsive reduction in transcriptional activity of HSC70, HIF1A, Mcl-1, Hsp90 and BIRC4.
Hif1a↓,
Mcl-1↓,
HSP90↓,
FLT4↓, A dose-dependent drop in mRNA levels of FLT4, EPHB4, DNAPK, PARP1, ATM, perlecan, GnTV and heparanase genes was observed after treatment of PC-3
cells with quercetin
EphB4↓,
DNA-PK↓,
PARP1↓,
ATM↓,
XIAP↝,
PLC↓,
GnT-V↝,
heparanase↝,
NM23↑, quercetin significantly exerted a dose-responsive rise in transcriptional levels of NM23 and CSR1 genes
CSR1↑,
SPP1↓, coupled with an expressive lowering in mRNA levels of SPP1, DNMT1, HDAC4, CXCR4, b-catenin and NHE1.
DNMT1↓,
HDAC4↓,
CXCR4↓,
β-catenin/ZEB1↓,
FBXW7↝,
AMACR↓,
cycD1/CCND1↓,
IGF-1R↓, down-regulation of mRNA levels of AMACR, cyclin D1, NOS2A, IGF1R, IMPDH1, IMPDH2 and HEC1
IMPDH1↓,
IMPDH2↓,
HEC1↓,
NHE1↓,
NOS2↓,
HDAC4↓, Qu treatment (50 µM Qu) for 48h downregulated HDAC4, NRF2 and p-NRF2 at protein levels (p<0.05; p<0.005; p<0.005 respectively).
NRF2↓,
p‑NRF2↓,
miR-133a-3p↑, miR-1, miR-133a/b, which target anti-apoptotic genes and miR-206, a pro apoptotic miR, were validated in xenograft model samples, resulting in a significant up-regulation of the expression levels in treated animals
miR-206↑,
| - |
in-vitro, |
BC, |
MCF-7 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vitro, |
BC, |
SkBr3 |
|
|
|
TumCCA↑, SFN (5-10 µM) promoted cell cycle arrest, elevation in the levels of p21 and p27 and cellular senescence
P21↑,
p27↑,
NO↑, effects were accompanied by nitro-oxidative stress, genotoxicity and diminished AKT signaling
Akt↓,
ATP↓, decreased pools of ATP and AMPK activation, and autophagy induction
AMPK↑,
TumAuto↑,
DNMT1↓, decreased levels of DNA methyltransferases (DNMT1, DNMT3B)
HK2↓, A decrease in HK2 levels was observed in SFN-treated MDA-MB-231 cells
PKM2↓, and a decrease in PKM2 levels was noticed in SFN-treated MDA-MB-231 and SK-BR-3 cells
HDAC3↓, . In contrast, HDAC3 , HDAC4 , HDAC6 , HDAC7 , HDAC8 ), HDAC9 and HDAC10 (histone deacetylase 10) mRNA levels were decreased in SFN-treated MDA-MB-231 cells
HDAC4↓,
HDAC8↓,
DNMT1↓, In this review, we highlight TQ as a potential multitarget single epidrug that functions by targeting the UHRF1/DNMT1/HDAC1/G9a complex
HDAC1↓,
TumCCA↑, inhibition of cell division, promotion of cell cycle arrest, activation of ROS production, induction of apoptosis and inhibition of tumor angiogenesis and metastasis
ROS↑,
Apoptosis↑,
angioG↓,
TumMeta↓,
selectivity↑, When compared to its effects on cancer cells, TQ has no or only mild cytotoxic effects on matched normal cells, such as normal human fibroblast cells [
BioAv↓, poor pharmacokinetics and chemical stability of TQ
BioAv↓, TQ is heat and light-sensitive, and it has poor solubility in aqueous media, which affects its biodistribution
HDAC1↓, T-ALL TQ decreased in the expression of HDAC1, 4 and 9
HDAC4↓,
UHRF1↓, TQ induces auto-ubiquitination of UHRF1 and subsequent degradation in cancer cells [23] by targeting its RING domain, which is the only domain of the UHRF1 structure that exhibits enzymatic activity
selectivity↑, via a specific inhibition of UHRF1 expression levels in cancer cells without affecting its expression in normal human cells.
G9a↓, TQ could quite possibly inhibit G9a and/or delocalize it from chromatin through its effects on UHRF1.
| - |
in-vitro, |
BC, |
MDA-MB-468 |
|
|
|
- |
in-vitro, |
AML, |
JK |
|
|
|
UHRF1↓, (UHRF1), DNMT1,3A,3B, G9A, HDAC1,4,9, KDM1B, and KMT2A,B,C,D,E, were downregulated in TQ-treated Jurkat cells
DNMT1↓,
DNMT3A↓,
DNMTs↓,
HDAC1↓,
HDAC4↓,
HDAC↓,
DLC1↑, several TSGs, such as DLC1, PPARG, ST7, FOXO6, TET2, CYP1B1, SALL4, and DDIT3, known to be epigenetically silenced in various tumors, including acute leukemia, were upregulated,
PPARγ↑,
FOXO↑,
TET2↑,
CYP1B1↑,
G9a↓, expression of UHRF1, DNMT1, G9a, and HDAC1 genes in both cancer cell (Jurkat cells and MDA-MB-468 cells) lines depends on the TQ dose
AntiCan↑, Thymoquinone is a natural product with anticancer activity.
Inflam↓, Thymoquinone has been shown to exert anti-inflammatory, antidiabetic, antihypertensive, antimicrobial, analgesic, immunomodulatory, spasmolytic, hepatoprotective, renal-protective, gastroprotective, bronchodilatory, antioxidant and antineoplastic eff
hepatoP↑,
RenoP↑,
BAX↑, Thymoquinone can upregulate proapoptotic genes and proteins, such as Bax/Bak, or downregulate antiapoptotic genes and proteins, such as Bcl-2, Bcl-xL, among others, as well as modulating the caspase pathway
Bak↑,
Bcl-2↓,
Bcl-xL↓,
ROS↑, through the generation of reactive oxygen species (ROS)
P53↑, overexpressed or activated by thymoquinone; for example, p53, PTEN, p21, p27 and breast cancer type 1 susceptibility protein (BRCA1), among others,
PTEN↑,
P21↑,
p27↑,
BRCA1↑,
PI3K↓, (PI3K)/Akt and mitogen-activated protein kinase (MAPK)/ERK, have been found to be inhibited by thymoquinone
Akt↓,
MAPK↓,
ERK↓,
p‑ERK↓, thymoquinone reduces ERK phosphorylation and matrix metalloproteinase (MMP) secretion by downregulating focal adhesion kinase (FAK)
MMPs↓,
FAK↓,
Twist↓, downregulates Twist1 and Zeb1 transcription factors, and thus inhibits epithelial to mesenchymal transition (EMT) and subsequently inhibits cancer metastasis
Zeb1↓,
EMT↓,
TumMeta↓,
angioG↓, thymoquinone can inhibit angiogenesis by interfering with essential steps of neovascularization, such as suppressing proangiogenic vascular endothelial growth factor (VEGF)
VEGF↓,
HDAC↓, HDACs are usually overexpressed in MCF-7 breast cancer cells, and thymoquinone can act as a HDAC inhibitor (HDACi) that potently induces apoptosis through inducing acetylation of histones and inhibiting deacetylation of histones.
Maspin↑, thymoquinone reactivates HDAC target genes (p21 and Maspin), inducing the upregulation of Bax
SIRT1↑, thymoquinone can upregulate SIRT1 expression in neonatal rat cardiomyocytes and consequently deacetylates p53; thus, it can act as an apoptosis inducer
DNMT1↓, Collectively, they suggested that thymoquinone induces methylation of DNA via binding with DNMT1 and suppressing its expression,
DNMT3A↓, thymoquinone decreases the expression of some important epigenetic proteins like DNMT1,3A,3B, G9A, HDAC1,4,9, KDM1B, KMT2A,B,C,D,E and UHRF1 in Jurkat cells,
HDAC1↓,
HDAC4↓,
Showing Research Papers: 1 to 8 of 8
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
NRF2↓, 1, p‑NRF2↓, 1, ROS↑, 2,
Mitochondria & Bioenergetics ⓘ
ATP↓, 1, XIAP↝, 1,
Core Metabolism/Glycolysis ⓘ
AMACR↓, 1, AMPK↑, 1, HK2↓, 1, PKM2↓, 1, PPARα↝, 1, PPARγ↑, 1, SIRT1↑, 1,
Cell Death ⓘ
Akt↓, 2, Apoptosis↑, 1, aSmase↝, 1, Bak↑, 1, BAX↑, 1, Bcl-2↓, 1, Bcl-xL↓, 1, CSR1↑, 1, Diablo↑, 1, Fas↓, 1, hTERT/TERT↓, 1, MAPK↓, 2, Mcl-1↓, 1, MDM2↓, 1, p27↑, 2,
Kinase & Signal Transduction ⓘ
Sp1/3/4↓, 1,
Transcription & Epigenetics ⓘ
EZH2↓, 1, SPP1↓, 1,
Protein Folding & ER Stress ⓘ
Hsc70↓, 1, HSP90↓, 1,
Autophagy & Lysosomes ⓘ
TumAuto↑, 1,
DNA Damage & Repair ⓘ
ATM↓, 1, BRCA1↑, 1, CYP1B1↑, 1, DNA-PK↓, 1, DNMT1↓, 6, DNMT3A↓, 3, DNMTs↓, 2, G9a↓, 2, P53?, 1, P53↑, 1, PARP1↓, 1, TP53↑, 1, UHRF1↓, 2,
Cell Cycle & Senescence ⓘ
cycD1/CCND1↓, 1, P21↑, 2, TumCCA↑, 2,
Proliferation, Differentiation & Cell State ⓘ
CD24↓, 1, EMT↓, 2, ERK↓, 1, p‑ERK↓, 1, FBXW7↝, 1, FOXO↑, 1, HDAC↓, 2, HDAC1↓, 4, HDAC2↓, 1, HDAC3↓, 2, HDAC4↓, 8, HDAC8↓, 1, IGF-1R↓, 1, NOTCH1↝, 1, PI3K↓, 2, PTEN↑, 2, STAT3↓, 1, TumCG↓, 1, Wnt↓, 1,
Migration ⓘ
AP-1↝, 1, DLC1↑, 1, E-cadherin↑, 1, EphB4↓, 1, FAK↓, 2, GnT-V↝, 1, heparanase↝, 1, miR-133a-3p↑, 1, miR-206↑, 1, MMP-10↓, 1, MMP2↓, 2, MMP7↓, 1, MMP9↓, 1, MMPs↓, 1, NM23↑, 1, Rho↓, 1, TumCI↓, 1, TumCMig↓, 1, TumCP↓, 1, TumMeta↓, 3, Twist↓, 1, Zeb1↓, 1, β-catenin/ZEB1↓, 2,
Angiogenesis & Vasculature ⓘ
angioG↓, 2, FLT4↓, 1, Hif1a↓, 1, Hif1a↝, 1, NO↑, 1, VEGF↓, 1,
Barriers & Transport ⓘ
NHE1↓, 1,
Immune & Inflammatory Signaling ⓘ
CXCR4↓, 1, IL6↓, 1, Inflam↓, 1, NF-kB↓, 1,
Cellular Microenvironment ⓘ
PLC↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↓, 2, selectivity↑, 2, TET2↑, 1,
Clinical Biomarkers ⓘ
BRCA1↑, 1, EZH2↓, 1, HEC1↓, 1, hTERT/TERT↓, 1, IL6↓, 1, Maspin↑, 1, NOS2↓, 1, TP53↑, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, hepatoP↑, 1, IMPDH1↓, 1, IMPDH2↓, 1, RenoP↑, 1,
Total Targets: 119
Pathway results for Effect on Normal Cells:
Total Targets: 0
Scientific Paper Hit Count for: HDAC4, Histone deacetylases
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:407 State#:% Dir#:1
wNotes=on sortOrder:rid,rpid
Home Page